Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limitedverified

TAK

Price:

$13.12

Market Cap:

$6.46T

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brand...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2010-01-05

Stock Exchange

NYSE

Ticker

TAK

The PE Ratio as of May 2024 (TTM) for Takeda Pharmaceutical Company Limited (TAK) is 45.24

According to Takeda Pharmaceutical Company Limited’s latest financial reports and current stock price. The company's current PE Ratio is 45.24. This represents a change of -166.81% compared to the average of -67.72 of the last 4 quarters.

Takeda Pharmaceutical Company Limited (TAK) Historical PE Ratio (quarterly & annually)

How has TAK PE Ratio performed in the past?

The mean historical PE Ratio of Takeda Pharmaceutical Company Limited over the last ten years is 22.54. The current 45.24 PE Ratio has changed 19.97% with respect to the historical average. Over the past ten years (40 quarters), TAK's PE Ratio was at its highest in in the March 2020 quarter at 367.72. The PE Ratio was at its lowest in in the March 2024 quarter at -269.34.

Quarterly (TTM)
Annual

Average

22.54

Median

21.76

Minimum

-32.35

Maximum

57.26

Takeda Pharmaceutical Company Limited (TAK) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Takeda Pharmaceutical Company Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 109.49%

Maximum Annual PE Ratio = 57.26

Minimum Annual Increase = -253.97%

Minimum Annual PE Ratio = -32.35

Quarterly (TTM)
Annual
YearPE RatioChange
202422.51109.49%
202310.75-9.90%
202211.9342.16%
20218.39-85.35%
202057.2642.42%
201940.2091.41%
201821.00-41.52%
201735.91-27.90%
201649.81-253.97%
2015-32.35-188.96%

Takeda Pharmaceutical Company Limited (TAK) Average PE Ratio

How has TAK PE Ratio performed in the past?

The current PE Ratio of Takeda Pharmaceutical Company Limited (TAK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

15.06

5-year avg

22.17

10-year avg

22.54

Takeda Pharmaceutical Company Limited (TAK) PE Ratio vs. Peers

How is TAK’s PE Ratio compared to its peers?

Takeda Pharmaceutical Company Limited’s PE Ratio is greater than Viatris Inc. (-221.78), greater than Elanco Animal Health Incorporated (-6.36), greater than Zoetis Inc. (32.58), greater than Emergent BioSolutions Inc. (-0.44), greater than Prestige Consumer Healthcare Inc. (15.23), greater than Amphastar Pharmaceuticals, Inc. (13.48), greater than Deciphera Pharmaceuticals, Inc. (-11.71), greater than Pacira BioSciences, Inc. (19.59), greater than Collegium Pharmaceutical, Inc. (11.87), greater than SIGA Technologies, Inc. (6.69), greater than Indivior PLC (-52.20), greater than Esperion Therapeutics, Inc. (-4.17), greater than Catalent, Inc. (-9.00), greater than Evotec SE (-8.60), greater than Eagle Pharmaceuticals, Inc. (2.57), greater than Neurocrine Biosciences, Inc. (37.63), less than Phibro Animal Health Corporation (57.02), greater than Teva Pharmaceutical Industries Limited (-37.81), greater than Haleon plc (27.93), greater than Bausch Health Companies Inc. (-112.62),

Build a custom stock screener for Takeda Pharmaceutical Company Limited (TAK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Takeda Pharmaceutical Company Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Takeda Pharmaceutical Company Limited (TAK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Takeda Pharmaceutical Company Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Takeda Pharmaceutical Company Limited's PE Ratio?

How is the PE Ratio calculated for Takeda Pharmaceutical Company Limited (TAK)?

What is the highest PE Ratio for Takeda Pharmaceutical Company Limited (TAK)?

What is the 3-year average PE Ratio for Takeda Pharmaceutical Company Limited (TAK)?

What is the 5-year average PE Ratio for Takeda Pharmaceutical Company Limited (TAK)?

How does the current PE Ratio for Takeda Pharmaceutical Company Limited (TAK) compare to its historical average?